These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 27768280)

  • 21. Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor.
    Ståhl S; Branca RM; Efazat G; Ruzzene M; Zhivotovsky B; Lewensohn R; Viktorsson K; Lehtiö J
    J Proteome Res; 2011 May; 10(5):2566-78. PubMed ID: 21413766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of the EphA2 receptor intracellular region by phosphomimetic negative charges in the kinase-SAM linker.
    Lechtenberg BC; Gehring MP; Light TP; Horne CR; Matsumoto MW; Hristova K; Pasquale EB
    Nat Commun; 2021 Dec; 12(1):7047. PubMed ID: 34857764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-Based Design of Novel EphA2 Agonistic Agents with Nanomolar Affinity in Vitro and in Cell.
    Gambini L; Salem AF; Udompholkul P; Tan XF; Baggio C; Shah N; Aronson A; Song J; Pellecchia M
    ACS Chem Biol; 2018 Sep; 13(9):2633-2644. PubMed ID: 30110533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structures of an Eph receptor tyrosine kinase and its potential activation mechanism.
    Wei Q; Liu J; Wang N; Zhang X; Jin J; Chin-Sang I; Zheng J; Jia Z
    Acta Crystallogr D Biol Crystallogr; 2014 Dec; 70(Pt 12):3135-43. PubMed ID: 25478832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Restriction of receptor movement alters cellular response: physical force sensing by EphA2.
    Salaita K; Nair PM; Petit RS; Neve RM; Das D; Gray JW; Groves JT
    Science; 2010 Mar; 327(5971):1380-5. PubMed ID: 20223987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness.
    Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
    Biochem Biophys Res Commun; 2004 Aug; 320(4):1096-102. PubMed ID: 15249202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.
    Incerti M; Tognolini M; Russo S; Pala D; Giorgio C; Hassan-Mohamed I; Noberini R; Pasquale EB; Vicini P; Piersanti S; Rivara S; Barocelli E; Mor M; Lodola A
    J Med Chem; 2013 Apr; 56(7):2936-47. PubMed ID: 23489211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conformational Clamping by a Membrane Ligand Activates the EphA2 Receptor.
    Westerfield JM; Sahoo AR; Alves DS; Grau B; Cameron A; Maxwell M; Schuster JA; Souza PCT; Mingarro I; Buck M; Barrera FN
    J Mol Biol; 2021 Sep; 433(18):167144. PubMed ID: 34229012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Sam Domain of EphA2 Receptor and its Relevance to Cancer: A Novel Challenge for Drug Discovery?
    Mercurio FA; Leone M
    Curr Med Chem; 2016; 23(42):4718-4734. PubMed ID: 27804871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemical proteomics reveals the target landscape of 1,000 kinase inhibitors.
    Reinecke M; Brear P; Vornholz L; Berger BT; Seefried F; Wilhelm S; Samaras P; Gyenis L; Litchfield DW; Médard G; Müller S; Ruland J; Hyvönen M; Wilhelm M; Kuster B
    Nat Chem Biol; 2024 May; 20(5):577-585. PubMed ID: 37904048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EphA2 Receptor Unliganded Dimers Suppress EphA2 Pro-tumorigenic Signaling.
    Singh DR; Ahmed F; King C; Gupta N; Salotto M; Pasquale EB; Hristova K
    J Biol Chem; 2015 Nov; 290(45):27271-27279. PubMed ID: 26363067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative proteomics of kinase inhibitor targets and mechanisms.
    Daub H
    ACS Chem Biol; 2015 Jan; 10(1):201-12. PubMed ID: 25474541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting EphA2-Sam and Its Interactome: Design and Evaluation of Helical Peptides Enriched in Charged Residues.
    Mercurio FA; Marasco D; Di Natale C; Pirone L; Costantini S; Pedone EM; Leone M
    Chembiochem; 2016 Nov; 17(22):2179-2188. PubMed ID: 27763725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interactions of the EphA2 Kinase Domain with PIPs in Membranes: Implications for Receptor Function.
    Chavent M; Karia D; Kalli AC; Domański J; Duncan AL; Hedger G; Stansfeld PJ; Seiradake E; Jones EY; Sansom MSP
    Structure; 2018 Jul; 26(7):1025-1034.e2. PubMed ID: 29887500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New affinity probe targeting VEGF receptors for kinase inhibitor selectivity profiling by chemical proteomics.
    Ku X; Heinzlmeir S; Helm D; Médard G; Kuster B
    J Proteome Res; 2014 May; 13(5):2445-52. PubMed ID: 24712744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NMR studies of a heterotypic Sam-Sam domain association: the interaction between the lipid phosphatase Ship2 and the EphA2 receptor.
    Leone M; Cellitti J; Pellecchia M
    Biochemistry; 2008 Dec; 47(48):12721-8. PubMed ID: 18991394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. One-Bead-Two-Compound Thioether Bridged Macrocyclic γ-AApeptide Screening Library against EphA2.
    Shi Y; Challa S; Sang P; She F; Li C; Gray GM; Nimmagadda A; Teng P; Odom T; Wang Y; van der Vaart A; Li Q; Cai J
    J Med Chem; 2017 Nov; 60(22):9290-9298. PubMed ID: 29111705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and analysis of EphA2-SAM peptide ligands: A multi-disciplinary screening approach.
    Mercurio FA; Di Natale C; Pirone L; Marasco D; Calce E; Vincenzi M; Pedone EM; De Luca S; Leone M
    Bioorg Chem; 2019 Mar; 84():434-443. PubMed ID: 30576907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Point mutations in dimerization motifs of the transmembrane domain stabilize active or inactive state of the EphA2 receptor tyrosine kinase.
    Sharonov GV; Bocharov EV; Kolosov PM; Astapova MV; Arseniev AS; Feofanov AV
    J Biol Chem; 2014 May; 289(21):14955-64. PubMed ID: 24733396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting EPHA2 with Kinase Inhibitors in Colorectal Cancer.
    Tröster A; Jores N; Mineev KS; Sreeramulu S; DiPrima M; Tosato G; Schwalbe H
    ChemMedChem; 2023 Dec; 18(23):e202300420. PubMed ID: 37736700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.